Physician profile
Geri Bacu
NPI 1376582700
$6,122.72
in general payments reported to CMS, 2019-2025
24 companies · $315 in 2025
The $315 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,326 · 2020: $284 · 2021: $777 · 2022: $1,637 · 2023: $1,222 · 2024: $562 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,846 · Education: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,845.51 |
| Education | $253.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $862.19 | 2019-2023 | |
| Ucb, INC. | $677.59 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $673.50 | 2020-2024 | Tremfya |
| Amgen INC. | $666.13 | 2019-2025 | Enbrel, Tavneos, Krystexxa |
| Abbvie INC. | $606.71 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $592.01 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $455.53 | 2019 | |
| Mallinckrodt Hospital Products INC. | $369.67 | 2020-2023 | Acthar |
| Glaxosmithkline, LLC. | $323.35 | 2019-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.99 | 2019-2023 | Cyltezo, Ofev |
| Actelion Pharmaceuticals US, INC. | $195.01 | 2022-2024 | Opsumit, Uptravi |
| Sobi, INC | $117.92 | 2021-2024 | |
| Lilly USA, LLC | $64.17 | 2020-2022 | |
| Celgene Corporation | $58.10 | 2019 | |
| Organon LLC | $53.10 | 2024-2025 | Hadlima, Renflexis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $40.67 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $33.30 | 2023 | Idacio |
| Takeda Pharmaceuticals U.S.A., INC. | $20.98 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.50 | 2021 | |
| Tonix Medicines, INC. | $16.81 | 2025 | Tonmya |
| Teva Pharmaceuticals USA, INC. | $15.08 | 2025 | Simlandi |
| Medexus Pharma, INC. | $12.50 | 2019 | |
| Horizon Therapeutics Plc | $11.99 | 2022 | |
| Genentech USA, INC. | $11.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geri Bacu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.